Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
As a single agent, paclitaxel has a response rate of 33% and 25-29% in SCLC patients with
sensitive relapse and with resistant relapse, respectively. As a single agent, gemcitabine
also has a response rate 16% and 6-13% in SCLC patients with sensitive relapse and with
resistant relapse, respectively. Because of single-agent activity, different mechanism of
action, non-overlapping toxicities, and beneficial pharmacologic interaction, paclitaxel and
gemcitabine combinations are attractive for testing in clinical trials.